AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04558463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug
Study NCT04558463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75mg
Description: The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug
Study NCT05594316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trichloroacetic acid
Description: 5. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
Study NCT04030039 — intervention group
Intervention type: DRUG
Intervention: Interferon
Description: chronic hepatitis B patients with interferon therapy
Study NCT04030039 — intervention group
Intervention type: DRUG
Intervention: nucleoside analogues
Description: chronic hepatitis B patients with interferon therapy
Study NCT01667081 — intervention group
Intervention type: DRUG
Intervention: Grazoprevir
Description: Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
Study NCT00647153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
Study NCT00647153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: One day post infusion
Study NCT00647153 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 123 anti-CEA recombinant diabody T84.66
Description: 10mCi/mg
Study NCT01847430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
Study NCT03685864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture Embedding Acupuncture
Description: Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
Study NCT03685864 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
Study NCT04553848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
Study NCT04553848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
Study NCT04553848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
Study NCT04553848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Over ground training/standard of care
Description: Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~* Biomechanical Constraints~* Stability Limits~* Anticipatory Postural Adjustments~* Reactive Postural Response~* Sensory Orientation~* Stability in Gait
Study NCT01831921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Weight Loss
Description: Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
Study NCT01831921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Individual nutrition counseling will be delivered by a registered dietitian.
Study NCT02194062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal spray
Description: use 2-50 mcg sprays to each nostril two times per day
Study NCT02194062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide head upright
Description: (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
Study NCT02194062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide head forward
Description: (0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
Study NCT01903070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study NCT00763971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (LDX)
Description: 30, 50 or 70mg capsule once per day (Overencapsulated)
Study NCT00763971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: 18, 36, or 54mg tablet one per day (Overencapsulated)
Study NCT00763971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once per day (Overencapsulated)
Study NCT03195751 — intervention group
Intervention type: DEVICE
Intervention: Software development kit measurements
Description: This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
Study NCT03195751 — intervention group
Intervention type: DEVICE
Intervention: Manual Goniometer Measurements
Description: A manual goniometer was used to measure the range of motion of the shoulder.
Study NCT03226314 — intervention group
Intervention type: PROCEDURE
Intervention: stool sample
Description: study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
Study NCT03763240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BSE
Description: BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract.
Study NCT03763240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Administered at 625mg/m2 BID orally every day while on study.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered at 625mg/m2 BID orally every day while on study.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Administered at 625mg/m2 BID orally every day while on study.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin
Description: Administered day 1 of each cycle at 50mg/m2 IV.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Administered day 1 of each cycle at 50mg/m2 IV.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Administered day 1 of each cycle at 50mg/m2 IV.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 102
Description: Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 102
Description: Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Administered day 1 of each cycle at 60mg/m2 IV.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered day 1 of each cycle at 60mg/m2 IV.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Administered day 1 of each cycle at 60mg/m2 IV.
Study NCT00719550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
Study NCT04162496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Refyne
Description: Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
Study NCT04062773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRF
Description: time restricted feeding group
Study NCT04062773 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal timing of food intake
Description: no time restricted feeding
Study NCT01205438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Study NCT01205438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo every 2 weeks
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
Study NCT01205438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo every 4 weeks
Description: Administered via subcutaneous injection for 52 weeks.
Study NCT01017068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: 4g/100ml) dose: п gutt tid x 1/52
Study NCT01017068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (2g/100ml) dose: п gutt tid x 1/52
Study NCT01017068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (1g/100ml) dose: п gutt tid x 1/52
Study NCT01017068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (4g/100ml) dose: п gutt tid x 1/52
Study NCT00108186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
Study NCT03891342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus administration
Description: Fluid bolus administration either fast in 5 minutes or slow in 30minutes.
Study NCT02537548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02537548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroperitoneal Lymph Node Dissection
Description: Undergo RPLND
Study NCT02022085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha Attract System
Description: The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
Study NCT04475666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replenish protein group
Description: For patients with Body mass index(BMI) \<30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI >=30, use adjusted body weight
Study NCT04475666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protein group
Description: For patients with BMI \<30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI >=30, use adjusted body weight
Study NCT03890991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCOPE-DM
Description: The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
Study NCT03890991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCOPE-DM with 3 months' supply of glucometer
Description: Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
Study NCT03890991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCOPE-DM with 6 months' supply of glucometer
Description: Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
Study NCT02029820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RenalGuard
Description: Intravenous saline hydration matched with urine output, using the device Renalguard
Study NCT04442191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: This study will use convalescent plasma collected from those who have previously had COVID-19 and have been shown to have cleared the infection and made antibodies against the virus.
Study NCT04442191 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm of this study will use fresh frozen plasma that presumably does not contain antibodies against COVID-19.
Study NCT04114188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Immunoglobulin (Rabbit)
Description: 1st kidney transplant recipients (low risk: PRA/cPRA \< 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
Study NCT00915772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin
Description: Linagliptin tablet low dose + metformin tablet 500 mg bid
Study NCT00915772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin+metformin
Description: Linagliptin low dose tablet + metformin 1000 mg tablet bid
Study NCT00915772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg tablet bid
Study NCT00918853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of adenocarcinoma of the head of the pancreas
Description: quality standard for the resection of adenocarcinoma of the head of the pancreas
Study NCT03494751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart monitor
Description: Use of heart monitor device in the patients after acute myocardium infarct.
Study NCT03494751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No heart monitor
Description: Standard monitoring by nurses.
Study NCT02432313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Release Formulation x (MRx)
Description: Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
Study NCT01668407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT)
Description: Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
Study NCT01668407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Gait Training (TT)
Description: Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks.
Study NCT01062139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarlin (Levocetirizine)
Description: Combination therapy compared to mono therapy
Study NCT01062139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosalin (Petasites hybridus CO2 extract)
Description: Combination therapy compared to mono therapy
Study NCT01062139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosalin (Petasites hybridus CO2 extract)
Description: Combination therapy compared to mono therapy
Study NCT00380770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic HAART Triomune : d4T, 3TC, NVP
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d > 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)